A Swedish pharmaceutical firm specializing in orphan and niche products has announced raising $15 million in a Series C financing round.

Pharmalink AB, based in Stockholm, has raised 96 million kr ($15 million US) in Series C financing. The round was led by new investor Investinor, and several existing investors including Industrifonden.

The funds will be used to: prepare for studies with Busulipo, a drug for cancer patients prior to bone marrow transplants; complete the Phase IIb study with Nefecon, a potential disease-modifying treatment for patients with primary IgA nephropathy at risk of developing end-stage renal disease; seek commercial partners for its products outside the Nordic region, and facilitate licensing or acquisition of additional opportunities for commercialization in the Nordic region.

Busulipo has successfully undergone clinical trials with more than 90 patients, and Nefecon is approaching mid-stage trials that should end in late 2015.